Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells

Veterinary Journal

Volumn 175, Issue 1, 2008, Pages 126-129

  Tamura, Kyoichi ^a   Yamada, Misato ^a   Isotani, Mayu ^a   Arai, Hiroyoshi ^a   Yagihara, Hiroko ^a   Ono, Kenichiro ^b   Washizu, Tsukimi ^a   Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Canine; Delayed type hypersensitivity; Dendritic cells; Malignant melanoma; Vaccination

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; KEYHOLE LIMPET HEMOCYANIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL OBSERVATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOG DISEASE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; NONHUMAN; SKIN TEST; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; DOG DISEASES; DOGS; MELANOMA; SKIN NEOPLASMS; VACCINATION;

CANIS FAMILIARIS;

EID: 38749128741     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2006.11.005     Document Type: Article

References (17)

1. Ackermann B., Troger A., Glouchkova L., Korholz D., Gobel U., and Dilloo D. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klinische Padiatrie 216 (2004) 176-182
2. Baars A., Claessen A.M., van den Eertwegh A.J., Gall H.E., Stam A.G., Meijer S., Giaccone G., Meijer C.J., Scheper R.J., Wagstaff J., Vermorken J.B., and Pinedo H.M. Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients. Annals of Oncology 11 (2000) 965-970
3. Banchereau J., Ueno H., Dhodapkar M., Connolly J., Finholt J.P., Klechevsky E., Blanck J.P., Johnston D.A., Palucka A.K., and Fay J. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. Journal of Immunotherapy 28 (2005) 505-516
4. Catchpole B., Gould S.M., Kellett-Gregory L.M., and Dobson J.M. Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs. American Journal of Veterinary Research 64 (2003) 544-549
5. Cranmer L.D., Trevor K.T., and Hersh E.M. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunology, Immunotherapy 53 (2004) 275-306
6. de Vries I.J., Bernsen M.R., Lesterhuis W.J., Scharenborg N.M., Strijk S.P., Gerritsen M.J., Ruiter D.J., Figdor C.G., Punt C.J., and Adema G.J. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. Journal of Clinical Oncology 23 (2005) 5779-5787
7. Di Nicola M., Anichini A., Mortarini R., Bregni M., Parmiani G., and Gianni A.M. Human dendritic cells: natural adjuvants in antitumour immunotherapy. Cytokines, Cellular and Molecular Therapy 4 (1998) 265-273
8. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., Foley R., Kruth S., Liaw P.C., and Gauldie J. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. Journal of Veterinary Internal Medicine 19 (2005) 56-63
9. Hersey P., Menzies S.W., Halliday G.M., Nguyen T., Farrelly M.L., DeSilva C., and Lett M. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunology, Immunotherapy 53 (2004) 125-134
10. Isotani M., Katsuma K., Tamura K., Yamada M., Yagihara H., Azakami D., Ono K., Washizu T., and Bonkobara M. Efficient generation of canine bone marrow-derived dendritic cells. Journal of Veterinary Medical Science 68 (2006) 809-814
11. Koenig A., Wojcieszyn J., Weeks B.R., and Modiano J.F. Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma. Veterinary Pathology 38 (2001) 427-435
12. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D., and Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. Journal of Immunology 165 (2000) 5713-5719
13. + T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine 21 (2003) 869-876
14. Ohashi E., Hong S.H., Takahashi T., Nakagawa T., Mochizuki M., Nishimura R., and Sasaki N. Effect of retinoids on growth inhibition of two canine melanoma cell lines. Journal of Veterinary Medical Science 63 (2001) 83-86
15. Salcedo M., Bercovici N., Taylor R., Vereecken P., Massicard S., Duriau D., Vernel-Pauillac F., Boyer A., Baron-Bodo V., Mallard E., Bartholeyns J., Goxe B., Latour N., Leroy S., Prigent D., Martiat P., Sales F., Laporte M., Bruyns C., Romet-Lemonne J.L., Abastado J.P., Lehmann F., and Velu T. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumour cell lysate. Cancer Immunology, Immunotherapy 55 (2006) 819-829
16. Slingluff C.L.Jr., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., Patterson J.W., Deacon D.H., Hibbitts S., Teates D., Neese P.Y., Grosh W.W., Chianese-Bullock K.A., Woodson E.M., Wiernasz C.J., Merrill P., Gibson J., Ross M., and Engelhard V.H. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. Journal of Clinical Oncology 21 (2003) 4016-4026
17. Takeda A., Homma S., Okamoto T., Kufe D., and Ohno T. Immature dendritic cell/tumour cell fusions induce potent antitumor immunity. European Journal of Clinical Investigation 33 (2003) 897-904